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Abstract
Targeted overexpression of an ornithine decarboxylase (ODC) transgene to mouse skin (the K6/
ODC mouse) significantly enhances susceptibility to carcinogenesis. While in most strain
backgrounds the predominant tumor type resulting from initiation-promotion protocols is benign
squamous papilloma, K6/ODC mice on a FVB/N background develop malignant squamous cell
carcinomas (SCCs) rapidly and in high multiplicity after carcinogen treatment. We have investigated
the utility of polyamine-based therapy against SCCs in this model using the ODC inhibitor 2-
difluoromethylornithine delivered orally. At a 2% concentration in drinking water, DFMO caused
rapid tumor regression, but in most cases, tumors eventually regrew rapidly even in the presence
of DFMO. The tumors that regrew were spindle cell carcinomas, an aggressive undifferentiated
variant of SCC. At 1% DFMO in the drinking water, tumors also responded rapidly, but tumor
regrowth did not occur. The majority of DFMO-treated SCCs were classified as complete
responses, and in some cases, apparent tumor cures were achieved. The enzymatic activity of
ODC, the target of DFMO, was substantially reduced after treatment with 1% DFMO and the high
SCC polyamine levels, especially putrescine, were also significantly lowered. Based on the results
of BrdUrd labeling and TUNEL assays, the effect of DFMO on SCC growth was accompanied by a
significant reduction in tumor proliferation with no increase in the apoptotic index. These results
demonstrate that SCCs, at least in the mouse, are particularly sensitive to polyamine-based
therapy.
Introduction
Targeted overexpression of ornithine decarboxylase
(ODC) to mouse epidermal keratinocytes with a bovine
keratin 6 (K6) promoter/regulatory region greatly
increases susceptibility to skin tumor development [1]. In
fact, in the K6/ODC transgenic model, treatment with
exogenous tumor promoters such as 12-0 tetradecanoyl-
phorbol-13-acetate (TPA) is dispensable: a maximal
tumor response occurs after a single initiating application
of a carcinogen such as 7, 12-dimethlybenz(a)anthracene
(DMBA). The increased activity of the ODC transgene in
this model is clearly necessary for the enhanced suscepti-
bility phenotype as exposure of initiated mice to the ODC
inhibitor 2 – difluoromethylornithine (DFMO) com-
pletely prevents papilloma development [2]. Addition-
ally, expression of the transgene is also important for
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maintenance of papilloma growth as DFMO treatment of
papilloma-bearing mice causes complete tumor regres-
sion [2].
The predominant tumor type induced in most mouse
models of skin cancer, especially those involving initia-
tion/promotion protocols, is benign squamous papil-
loma. Squamous cell carcinomas, if they develop at all,
are a small fraction of total tumors and appear with a long
latency (6–12 months). Recently, a PKC-ε transgenic
mouse (on an FVB background) has been reported to
develop predominantly squamous cell carcinomas after a
DMBA/TPA protocol [3]. Similarly, when the K6/ODC
transgene was placed on a congenic FVB background,
SCCs developed rapidly and in high multiplicity after
DMBA exposure [4]. Finally, a bi-transgenic K6/ODC;
TG.AC model [on a (FVB × B6)F1 background] develop
SCCs spontaneously due to the combined effects of ODC
overexpression and the v-Ha-ras gene present in the
TG.AC line [5]. The common feature of all these recently
developed transgenic mouse models of SCC is the FVB
genetic background, indicating the presence of SCC-pre-
disposing genes in this strain. In the FVB/N strain itself,
Hennings et al reported a higher percentage of papillomas
progressed to SCCs in this strain than is typical of other
susceptible strains [6].
Because of the short latency and high multiplicity of SCCs
in the K6/ODC (FVB) model, it could serve as a useful pre-
clinical model of human SCC. Specifically, existing or
novel therapeutic approaches against SCC could be evalu-
ated in this model. Because of the effectiveness of DFMO
as a therapy for squamous papillomas, we have evaluated
this drug as single-agent therapy for SCC. Our results dem-
onstrate that murine SCCs are remarkably sensitive to
DFMO treatment, suggesting that polyamine-based ther-
apy may be a novel approach to the treatment of human
SCC.
Methods
Animals and treatments
The K6/ODC model on the FVB/N strain background
instead of the original C57BL/6J background was used in
all experiments. To induce SCCs, newborn (1 day old)
pups were treated with a single dose of 200 nmol of 7,12-
dimethylbenz[a]anthracene (DMBA) dissolved in 50 µl
acetone applied to the dorsal skin. Treatment area was
approximately 40–50 mm2. SCCs typically developed on
the treated area beginning 5 weeks later. SCC bearing mice
with tumor volumes in the range 250–1500 mm3 were
randomized to experimental groups between 8 and 16
weeks of age.
Groups of tumor-bearing mice (n = 5–18) were treated
with DFMO dissolved at 1 or 2% in the drinking water.
DFMO solutions were changed every 4 days or less. Ani-
mals were observed daily for signs of distress due to tumor
burden and/or DFMO treatment. Tumor volume was cal-
culated according to the equation   where l =
length (longest dimension) and w = width.
Tumor harvest, ODC and polyamine measurements
SCC-bearing mice were rapidly euthanized, SCCs excised,
and a piece or pieces placed in Fekete's fixative for his-
topathologic diagnosis and the remaining tumor was
placed immediately on dry ice and transferred to -80°C
for subsequent biochemical determinations. Tumor-bear-
ing mice used for these analyses were randomized by
tumor size for placement into control or DFMO-treated
groups. ODC activity and polyamine levels were meas-
ured in buffer extracts and 0.2 N PCA extracts of tissue,
respectively [7]. Buffer extracts for ODC determination
from DFMO-treated mice were dialyzed overnight vs
1000-fold excess of buffer to remove free DFMO. One unit
of ODC activity corresponds to 1 nmol of C02 liberated/h.
ODC specific activity is expressed as units/mg protein.
Polyamine levels are expressed as nmol/mg DNA.
Measurement of apoptosis and cell proliferation in SCCs
Tumor-bearing mice were injected i.p. with BrdUrd (100
µg/g body weight) 1 hour before sacrifice. Mice were ran-
domized into control and DFMO-treatment groups based
on tumor size. Pieces of tumor were fixed overnight in
Fekete's solution and processed for paraffin embedding.
Assessment of apoptotic and cell proliferation indices was
performed using a TUNEL-based assay and detection of
incorporation of BrdUrd into nuclei, respectively, as pre-
viously described [2]. Differences in these parameters
between control and treatment groups were assessed by
ANOVA using StatView® (SAS Institute).
Results
Efficient induction of cutaneous SCCs in K6/ODC (FVB) 
mice
We have previously reported the propensity of K6/ODC
mice (founder line 55/2 m) on an FVB background to
develop SCCs rapidly after a single dose of 200 nmol
DMBA [4]. Due to breeding problems with 55/2 m
founder line, mice from a second founder line 39/1m
were treated with a single dose of DMBA (either 50 or 200
nmol) to determine if SCCs are also induced in this line.
[The papilloma response of these two lines on a C57BL/6J
background is identical [8].] The results (Figure 1) con-
firm the high sensitivity of K6/ODC (FVB) mice from this
founder line to SCC induction: maximal SCC multiplici-
ties of 2.1 ± 0.3 and 4.3 ± 0.6 were observed in mice
treated with 50 and 200 nmol DMBA, respectively. For the
studies described, mice from both founder lines were
used. The latent period for SCC appearance in this model
V =
× lw 2
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is remarkably short, 5–6 weeks, compared to other mod-
els (typically 6 months or longer). As previously reported
[4], the majority of tumors that developed were SCCs, not
benign papillomas typically found in most other models.
Effect of DFMO on growth of murine SCCs
Based on the therapeutic effect of DFMO on papillomas in
both C57BL/6(B6) and K6/ODC(B6) mice [2], SCC-bear-
ing K6/ODC(FVB) mice were administered DFMO in the
drinking water at a concentration of 2% (w/v). The SCCs
exhibited a biphasic response to DFMO: there was a pro-
nounced volume reduction of each tumor over the first
two weeks of treatment, followed in five of six cases by a
rapid regrowth of the tumor in the continued presence of
DFMO (Figure 2). When the tumors that regrew were
examined histologically, all were diagnosed either as spin-
dle cell carcinomas or mixed squamous cell and spindle
cell carcinoma. Immunostaining with an anti-keratin
antibody confirmed the diagnosis as spindle cell carcino-
mas (as opposed to undifferentiated sarcomas). Spindle
cell carcinomas are an anaplastic, highly aggressive, vari-
ant of SCC in the mouse [9]. A typical squamous cell car-
cinoma and spindle cell carcinoma are shown in Fig 3.
The extremely rapid regrowth of the spindle cell carcino-
mas in the continued presence of DFMO raised the
question whether ODC activities and polyamine levels
Dose-dependent induction of SCCs in K6/ODC(FVB) mice of founder line 39/1m Figure 1
Dose-dependent induction of SCCs in K6/ODC(FVB) mice of founder line 39/1m. Newborn mice (1 day old) were treated 
with either 50 nmol (● ) or 200 nmol (■ ) DMBA dissolved in 50 ul acetone. Visible tumors occurred as early as 5 weeks after 
treatment and SCCs were quantitated beginning at 8 or 10 weeks after treatment. Results are given as mean number of SCCs 
per mouse ± S.E. There were 10 mice in the 50 nmol group and 18 mice in the 200 nmol group.
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were affected in these tumors. Prior to treatment, SCCs
express abundant levels of ODC and polyamine levels,
especially putrescine, are extraordinarily high (Table 1).
In contrast, the spindle cell carcinomas express, in gen-
eral, low levels of ODC and greatly reduced polyamine
levels. The one spindle cell carcinoma with moderately
elevated ODC and polyamine levels was actually a mixed
tumor composed of both squamous cell carcinoma and
spindle cell carcinoma components, suggesting the
former contributes most of the measured ODC activity
and polyamines. These results indicate that excessively
elevated ODC and polyamines are not required for
growth of spindle cell carcinomas.
A second, larger, study was conducted to determine the
response of SCCs to 1% DFMO. Compared to control
SCC-bearing mice, after a one-week lag period, tumor-
bearing mice administered 1% DFMO exhibited a rapid
reduction in tumor volume (figure 4). The response of
individual tumors to 1% DFMO is shown in Table 2: of
the 16 SCCs, 15 responded with at least an 80% volume
reduction while 1 tumor was non-responsive (17A). Of 8
tumors evaluable after 10 weeks of observation, (2 mice
Response of SCCs to 2% DFMO in the drinking water Figure 2
Response of SCCs to 2% DFMO in the drinking water. Five K6/ODC(FVB) mice of founder line 55/2m bearing 6 SCCs were 
administered 2% DFMO in the drinking water and tumor volumes measured weekly over the course of treatment. Individual 
tumors are indicated by use of different symbols. Initial tumor volumes ranged from 279–1238 mm3. All mice were eventually 
sacrificed with large tumor burdens due to a rapidly growing subcutaneous tumor. Tumor volume ratio is defined as the tumor 
volume after DFMO treatment divided by the initial tumor volume.
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with 8 SCCs died unexpectedly after 6–7 weeks on
DFMO), five tumors (62.5%) exhibited complete
responses and 1 responded with a >95% reduction in
tumor volume. For 2 of the tumors that responded com-
pletely, (14A and 20A) a follow-up period of 5–6 weeks
indicated no tumor regrowth after cessation of DFMO
therapy. Thus, in contrast to the results with 2% DFMO
(Figure 2), we observed no outgrowth of highly aggressive
spindle cell carcinomas after treatment with 1% DFMO,
and in fact some SCCs appear to have been cured by this
therapy. However, studies involving a longer follow-up
period than 5–6 weeks are required to reach definite con-
clusions regarding tumor cures after DFMO therapy.
Effect of DFMO on ODC activity and polyamine levels
In order to determine the effect of DFMO on its only
known target, we measured ODC activities in tumors fol-
lowing 1% DFMO treatment for 1–8 days. This period was
Histology of SCCs vs spindle cell carcinomas Figure 3
Histology of SCCs vs spindle cell carcinomas. (A) A typical well-differentiated SCC is shown. (B) Morphology of a spindle cell 
carcinoma that regrew in the presence of 2% DFMO (figure 2). Note the small, tightly packed fibroblastic cells with loss of epi-
thelial features in the spindle cell carcinoma. The prominent epithelial cysts are a feature of normal K6/ODC skin [1].
Table 1: ODC and polyamine levels in SCCs vs. spindle cell carcinomas. Portions of 5 histologically confirmed SCCs from 5 different 
mice and the 5 spindle cell carcinomas from Figure 2 were harvested for measurement of ODC activity and polyamine levels as 
described in Methods. Results shown are mean ± S.E. Abbreviations: Pu, Putrescine; Spd, Spermidine; Sp, Spermine
ODC Specific Activity units/mg protein Polyamines nmol/mg DNA
Tumor type Mean ± S.E. Range Pu Spd Sp Total
SCC 126 ± 38 16.7 – 251 1543 ± 604 306 ± 68 79 ± 35 1928
Spindle Cell Carcinomas 1.6 ± 1.2 0.11 – 7.1 14.1 ± 2.9 68.7 ± 25 54.7 ± 18 138
A
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chosen based on previous results in squamous papillomas
[2]. Control SCCs expressed very high levels of ODC,
albeit with a substantial variability from tumor to tumor
(Table 3). DFMO treatment led to a rapid and substantial
decrease in SCC ODC activity; as early as 24 hours after
the start of DFMO therapy, the mean ODC activity was
reduced by 91% (Table 3). By 8 days after DFMO, ODC
activity was reduced by greater than 96%. Despite very
high levels of pretreatment ODC activity, DFMO adminis-
tered p.o. was able to rapidly normalize enzyme levels to
values typical of K6/ODC epidermis [4].
We also measured polyamine levels in the same tumors
used for ODC analyses. As expected based on previous
studies of benign tumors in this model [2], putrescine is
the most abundant polyamine in untreated SCCs, pre-
sumably due to the high level of ODC expression com-
pared to downstream enzymes in putrescine metabolism
(S-adenosyl-L-methionine decarboxylase, spermidine
synthase). After 1% DFMO treatment, SCC polyamine lev-
els, especially putrescine, declined rapidly (Table 3). As
early as 24 hours after drug treatment, putrescine levels
were reduced 71%. After 8 days of treatment, putrescine
levels were reduced 88% from untreated SCC levels. Sper-
midine and spermine levels also declined by approxi-
mately 50% over the 8-day treatment period.
Effect of DFMO on tumor proliferation and apoptotic 
index
To investigate the mechanism of DFMO-induced SCC
regression, we measured the proliferation index and frac-
tion of cells undergoing apoptosis in untreated and 1%
DFMO-treated tumor-bearing mice. Consistent with pre-
vious results with benign squamous papillomas [2],
DFMO treatment did not cause an increase in the number
of cells undergoing apoptosis in SCCs. (Table 4). Instead,
at 48 hours and later after treatment, a significant reduc-
tion in apoptotic cells was observed. These results indicate
that an induction of a large number of apoptotic cells after
DFMO treatment is not involved in the early response of
SCCs to DFMO, although we can not rule out a role for
apoptosis at later times following DFMO therapy.
In marked contrast to the apoptotic index, DFMO had a
rapid effect on tumor proliferation (Table 5). The percent-
age of BrdUrd-positive cells was decreased as early as 24
hours after DFMO therapy, reached a maximum at 48
hours (73% inhibition), and was significantly decreased
through 8 days of treatment. As described earlier,
polyamine levels, especially putrescine, are decreasing
precipitously throughout this 8-day period. These results
are consistent with our previous studies in squamous skin
papillomas indicating a regulatory role for polyamines,
and in particular putrescine, in neoplastic growth [2].
Table 2: Response of individual tumors to treatment with 1% DFMO. SCC-bearing mice were administered 1% DFMO in the drinking 
water until all tumors had completely regressed, then transferred to regular drinking water to evaluate tumor recurrence. The values 
in bold represent the DFMO treatment period for each mouse. Tumor volume ratio is defined as the tumor volume after DFMO 
treatment divided by the initial pretreatment volume. There were 8 concurrent control mice with 13 total tumors, all of which 
increased in tumor volume throughout the experimental period (data not shown).
TUMOR VOLUME RATIO
Weeks after start of treatment
T u m o r  # 123456789 1 0
14A 0.18 0 0 0 000000
14B 0.12 0.02 0.01 0.01 0.01 0.01 0.03 0.04 0.08 0.03
16Aa 0.08 0.02 0.02 0 0.03 0.06
16B 1.19 0.31 0.16 0.05 0.02 0.02
16C 0.06 0.08 0.01 0 0 0
16D 1.60 0.21 0.02 0.01 0.02 0.02
16E 1.21 0.14 0.04 0 0 0
16F 1.43 0.15 0.19 0.04 0.09 0.03
16G 0.31 0.11 0.08 0.05 0.08 0.08
17A 2.03 1.90 2.19 2.25 2.29 2.74 1.40 1.69 1.35 2.07
18A 0.83 0.10 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0
19Ab 3.28 1.92 0.76 0.31 0.33 0.09 0
20Ac 0.77 0.03 0.02 0 0 0 0 000
21A 0.54 0.10 0.01 0.03 0.01 0.02 0.01 0 0 0
21B 0.77 0.25 0.20 0.15 0.17 0.19 0.37 0.58 0.97 0.97
21C 1 . 1 8 0 . 3 4 0 . 0 7 0 . 0 1 000000
aMouse died after 6 weeks of treatment bMouse died after 7 weeks of treatment cMouse was followed for 12 weeks with no recurrence of tumorJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/10
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Response of SCCs to 1% DFMO in the drinking water Figure 4
Response of SCCs to 1% DFMO in the drinking water. Seven K6/ODC(FVB) mice of founder line 39/1m bearing 16 SCCs were 
administered 1% DFMO (■ ) in their drinking water for 10 weeks (or less if complete tumor regression was observed). Control 
mice (● ) (n = 8, bearing 13 total tumors) received regular drinking water. The tumor volume ratio was measured weekly. Two 
mice with 8 SCCs with very low tumor burden died unexpectedly at 6 and 7 weeks of DFMO treatment. For individual tumor 
responses, see Table 2.
Table 3: Effect of DFMO on SCC ODC activity and polyamine levels. Untreated (control) SCC-bearing mice or mice administered 1% 
DFMO for the indicated times were sacrificed and portions of their SCCs quickly frozen and started at -80°C. Mice from founder line 
39/1m were used. Subsequently tumor extracts were prepared for measurement of ODC activity and polyamine levels as described in 
Methods. There were 6 control SCCs and 3–4 SCCs in the DFMO groups. Results are expressed as mean ± S.E. Control values for ODC 
activity and polyamine levels are taken from Table 1. Abbreviations: Pu, Putrescine; Spd, Spermidine; Sp, Spermine.
Polyamine nmol/mg DNA
Treatment ODC Specific 
Activity units/mg
P valueb Pu P value Spd P value Sp
Control 126 ± 38.2 - 1543 ± 04 - 306 ± 68 - 79 ± 35
DFMO, 24 hrs. 11.3 ± 1.2 0.07 445 ± 164 0.07 267 ± 29 0.65 38 ± 3.5
DFMO, 92 hrs. 7.2 ± 3.1 0.06 310 ± 121 0.06 172 ± 40 0.17 37 ± 15
DFMO, 192 hrs. 4.5a - 190 ± 47 0.03 153 ± 58 0.09 36 ± 9.9
aTwo SCCs were used for ODC determination. bCompared to control value (ANOVA).
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Discussion
On all inbred strain backgrounds examined to date,
expression of the K6/ODC transgene increases susceptibil-
ity of skin to tumor development [1,4] and unpublished
results]. On most strain backgrounds, the great majority
of tumors induced in this model after a single low dose of
a carcinogen such as DMBA are benign squamous papillo-
mas. On the FVB/N background however, DMBA induces
predominantly squamous cell carcinomas (Figure 1 and
reference [4]). The predisposition to SCC development of
K6/ODC (FVB) mice is consistent with the results of oth-
ers using different models on an FVB strain background
[3,5,6]. A unique feature of the K6/ODC(FVB) model is
the very short latency of tumor development (5–6 weeks)
and high tumor multiplicity (Figure 1). These properties
favor its utility as an autochthonous mouse model of SCC
development, amenable to rapid preclinical testing of new
therapeutic modalities.
Based on previous studies showing efficacy of the ODC
inhibitor DFMO against squamous papillomas in K6/
ODC B6 mice, we asked whether this drug would be effec-
tive against SCCs. The answer is clearly yes, although sig-
nificant differences exist in outcomes depending on the
dose of DFMO used. At a 2% dose level, all SCCs
responded initially with a substantial volume reduction,
but in the great majority of cases (83%) tumors rapidly
regrew in the continuous presence of DFMO. Interest-
ingly, these DFMO-resistant tumors were of a different
histologic type (spindle cell carcinoma or mixed spindle
cell/squamous cell carcinoma) and had markedly reduced
ODC and polyamine levels. It appears that this high con-
centration of DFMO selects for a "new" tumor type that
does not require high polyamine levels for growth. The
mechanism responsible for this selection process is not
known. However, since most DMBA-induced skin tumors
in K6/ODC (and other) mice contain a mutant c-Ha-ras
allele, a possible mechanism involves loss of the wild-type
c-Ha-ras allele as suggested by others [10]. This possibility
is currently under investigation.
Lowering the dose of DFMO to 1% greatly improved the
eventual therapeutic outcome: the early response of SCCs
to this dose was similar to mice treated with 2% DFMO,
but no spindle cell carcinomas emerged. It is presently not
clear why reducing the DFMO dose from 2% to 1% elim-
Table 4: Effect of DFMO on apoptotic index of SCCs. Tumor-bearing K6/ODC transgenic mice of founder line 39/1m were administered 
regular drinking water or water containing 1% DFMO. At the indicated time, animals in each group were sacrificed, and 3–5 
representative tumors were harvested for measurement of apoptotic frequency as described in Methods. Control mice (n = 4) were 
sacrificed at various time throughout the 8d experimental period. Results represent > 800 cells counted in multiple sections from each 
tumor.
Group No. of Cells Counted % Apoptotic Cells (mean ± SE) P value*
Control 5311 2.7 ± 0.4
DFMO, 1d 4100 2.6 ± 0.1 0.81
DFMO, 2d 3429 1.4 ± 0.5 0.035
DFMO, 4d 5831 1.4 ± 0.2 0.026
DFMO, 8d 4189 1.1 ± 0.1 0.013
* vs control value (ANOVA)
Table 5: Effect of DFMO on proliferative index of SCCs. Tumor-bearing K6/ODC transgenic mice of founder line 39/1m were 
administered 1% DFMO in their drinking water and sacrificed at the indicated times after the start of treatment. Control animals (n = 
4) received regular drinking water and were sacrificed at various times throughout the 8 day experimental period. One hour before 
sacrifice, mice were injected i.p. with BrdUrd (100 µg/g body weight), and tumors and surrounding skin were processed for 
immunocytochemistry as described in Methods. Results represent counts of > 800 cells/section with 3–5 tumors per group.
Group No. of Cells Counted % of Nuclei, BrdUrd-Positive (mean ± SE) P Value*
Control 4375 28.7 ± 3.6
DFMO, 1d 4696 21.2 ± 3.9 0.13
DFMO, 2d 4339 7.8 ± 1.0 0.007
DFMO, 4d 6202 13.3 ± 1.9 0.004
DFMO, 8d 2651 14.4 ± 1.9 0.009
*vs control value (ANOVA)Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/10
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inates the high rate of conversion of SCCs to spindle cell
carcinomas. However, the absence of such a transition
allowed us to evaluate the effect of long-term DFMO treat-
ment on SCCs. In the 1% DFMO treatment group, we
achieved a complete response rate of 62.5% (5/8) and a
partial response of 12.5%. Of the complete responders, at
least 2 tumors were apparently cured, based on the lack of
tumor regrowth over a 5–6 week period after cessation of
DFMO. To our knowledge, there are no published reports
of curative therapy using DFMO in any preclinical tumor
model. Looking forward to potential human trials in SCC
patients it should be emphasized that oral dose levels of
1–2 % used in this study are roughly 10–20 times higher
than has ever been administered to humans in early ther-
apeutic trials [11]. Ongoing studies are evaluating lower
doses of DFMO (more relevant to tolerable human doses)
to determine efficacy in this preclinical SCC model.
As opposed to human tumor xenografts [12-14] there
have been relatively few studies of the efficacy of DFMO
as a therapeutic agent against autochthonous rodent
tumors. Zhang, et al, demonstrated that 3% DFMO in the
drinking water retarded the growth of small colon tumors
(probably adenomas) in azoxymethane-treated rats [15].
These tumors eventually began to regrow in the presence
of DFMO, reminiscent of the current results with 2%
DFMO. Previous results from this laboratory demon-
strated complete regression of benign squamous papillo-
mas after 1% DFMO treatment in both C57BL/6J and K6/
ODC. C57BL/6J mice [2]. Finally, Lan, et al [16] reported
nearly complete regression of keratoacanthomas (a form
of SCC) after 1% DFMO in a model similar, in many
respects, to ours (bitransgenic K6/ODC; TG.AC mice on a
(B6 × FVB)F1 background); in this model spontaneous
SCC development is driven by the combined effect of a v-
Ha-ras  oncogene and ODC overexpression. Taken
together, our results and those of Lan, et al, indicated that
autochthonous squamous tumors, both benign and
malignant, appear to be particularly responsive to single
agent therapy with DFMO. In a study relevant to human
SCCs of the head and neck, DFMO at 1.5% inhibited both
the growth of SCC-derived cell lines in vitro and SCC
xenografts in athymic mice [17].
As expected, DFMO treatment rapidly inhibited the enzy-
matic activity of its only cellular target, ODC, and reduced
polyamine levels. A reduction in these parameters was
observed as early as 24 hours after DFMO administration
in the drinking water. In contrast to normal tissues,
putrescine accumulates to extraordinary levels in SCCs
and is the most abundant polyamine in these tumors. We
have speculated that putrescine, rather than spermidine
and/or spermine, is the regulatory polyamine for modu-
lating the neoplastic phenotype [2], but this question is
difficult to answer in a complex in vivo model. DFMO
over an 8-day period was able to reduce putrescine levels
by 88%, with lesser reductions in spermidine and sper-
mine levels. Over the same time period, the tumor prolif-
eration index was reduced by 50%. If the rate of cell loss
due to terminal differentiation remains the same during
the course of DFMO therapy, tumor volume reduction
could be explained simply by this effect of DFMO on
tumor proliferation. In this model of SCC, DFMO did not
cause an increase in apoptosis over the same period in
which polyamine levels are decreasing rapidly, tumor cell
proliferation is reduced, and tumor volume is shrinking.
In contrast, the apoptotic index actually decreased after
DFMO therapy. There are conflicting reports on the effect
of DFMO on apoptosis in various in vivo models. In a rat
model of esophageal squamous cell carcinoma driven by
zinc deficiency, Fung et al [18] reported an induction
(approximately 2.5 fold) of apoptosis after 1% DFMO
treatment in the esophageal epithelium. Similar results
have been reported in rat colonic adenomas [19] and
human gastric carcinoma xenographs [20]. In the bitrans-
genic K6/ODC; TG.AC model of SCC, very similar to the
model used in our studies, Lan et al [16] found that 1%
DFMO treatment increased the apoptotic index in both
small and large squamous tumors in the same time period
we have found a decrease in apoptotic index in SCCs
(Table 4). While the reason for these discordant results in
two very similar models are not readily apparent, there are
at least two significant differences between the models
that might explain the results. The SCCs in the K6/ODC
model were induced by DMBA, which causes a variety of
single point mutations in the c-Ha-ras and c-Ki-ras genes
[21]. In the bitransgenic K6/ODC; TG.AC model, tumors
developed spontaneously due to combined expression of
a strong, doubly-mutated v-Ha-ras oncogene and the K6/
ODC transgene. The second difference in the two models
is genetic background: FVB for the K6/ODC model and
(B6 × FVB)F1 for the bitransgenic model, raising the
intriguing possibility of modifier alleles in the B6 strain
capable of modifying the apoptotic response of SCCs to
DFMO. In human actinic keratoses, premalignant squa-
mous lesion of the skin, topical DFMO (10%) treatment
causes lesion regression [22]. This effect of DFMO
occurred without change in the apoptotic index [23], con-
sistent with our previous results in mouse squamous pap-
illomas. Taken together, these results suggest that the
apoptotic response of a tissue or tumor to DFMO may
depend on the complex interplay of several factors,
including tissue type, degree of malignancy, nature of the
genetic alterations present, and possibly genetic
background.
In summary, autochthonous mouse SCCs appear to be
very susceptible to therapy with DFMO. However, at the
highest dose tested (2%) the initial positive response of
SCCs was followed by the emergence of a histologicallyPublish with BioMed Central    and   every 
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different tumor, spindle cell carcinoma, which is resistant
to DFMO. This selection for DFMO-resistant tumor
growth did not occur at 1% dose level. While early
(reviewed in [24]) and more recent [25,26] trials of
DFMO against advanced cancers have been generally dis-
appointing, there are no published reports of the use of
DFMO against SCCs at any organ site. Upon further devel-
opment, human SCCs should be evaluated as candidates
for polyamine-based therapy using DFMO, either with or
without standard chemotherapy regimens.
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